Natera (San Carlos, California) has completed a $54.6 million financing round to support the expansion and continued global rollout of its non-invasive prenatal test, Panorama. The test uses fetal cell-free DNA found in maternal blood and works as early as nine weeks gestation, without risk to the fetus.